SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:21e16529-220d-419d-bead-d869f4adc585"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:21e16529-220d-419d-bead-d869f4adc585" > Serum TRACP 5b is a...

Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover

Nenonen, Arja (författare)
Cheng, Sulin (författare)
Ivaska, Kaisa, (författare)
University of Turku
visa fler...
Alatalo, Sari L (författare)
Lehtimaki, Terho (författare)
Schmidt-Gayk, Heinrich (författare)
Uusi-Rasi, Kirsti (författare)
Heinonen, Ari (författare)
Kannus, Pekka (författare)
Sievanen, Harri (författare)
Vuori, Ilkka (författare)
Vaananen, H Kalervo (författare)
Halleen, Jussi M (författare)
visa färre...
2005
Engelska.
Ingår i: Journal of Bone and Mineral Research. - AMBMR. - 1523-4681. ; 20:8, s. 1804-1812
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • We studied clinical performance of serum TRACP 5b and other bone turnover markers, including S-CTX, U-DPD, S-PINP, S-BALP, and S-OC, for monitoring alendronate treatment. TRACP 5b had higher clinical sensitivity, area under the ROC curve, and signal-to-noise ratio than the other markers. INTRODUCTION: The purpose of this study was to compare the clinical performance of serum TRACP 5b (S-TRACP5b) with that of other markers of bone turnover in the monitoring of alendronate treatment. MATERIALS AND METHODS: This double-blinded study included 148 healthy postmenopausal women that were randomly assigned into two groups: one receiving 5 mg alendronate daily (n=75) and the other receiving placebo (n=73) for 12 months. All individuals in both groups received calcium and vitamin D daily. The bone resorption markers S-TRACP5b, serum C-terminal cross-linked telopeptides of type I collagen (S-CTX), and total urinary deoxypyridinoline (U-DPD), and the serum markers of bone formation procollagen I N-terminal propeptide (S-PINP), bone-specific alkaline phosphatase (S-BALP), and total osteocalcin (S-OC) were assessed at baseline and at 3, 6, and 12 months after initiation of treatment. Lumbar spine BMD (LBMD) was measured at baseline and 12 months. RESULTS: Compared with the placebo group, LBMD increased, and all bone markers decreased significantly more in the alendronate group (p<0.001 for each parameter). The decrease of S-TRACP5b after first 3 months of alendronate treatment correlated significantly with the changes of all other markers except S-OC, the best correlation being with S-CTX (r=0.60, p<0.0001). The changes of LBMD at 12 months only correlated significantly with the changes of S-TRACP5b (r=-0.32, p=0.005) and S-CTX (r=-0.24, p=0.037) at 3 months. Based on clinical sensitivity, receiver operating characteristic (ROC) curves, and signal-to-noise ratio, S-TRACP5b, S-CTX, and S-PINP were the best markers for monitoring alendronate treatment. Clinical sensitivity, area under the ROC curve, and signal-to-noise ratio were higher for S-TRACP5b than for the other markers. CONCLUSION: These results show that S-TRACP5b, S-CTX, and S-PINP are useful markers for monitoring alendronate treatment.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Ortopedi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Orthopedics (hsv//eng)

Nyckelord

TRACP 5b
bone markers
alendronate
treatment monitoring
randomized study

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)
art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy